Masayuki Shiseki

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: June 06, 2023

Effective therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy with obinutuzumab for follicular lymphoma in leukemic phase

Effective therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy with obinutuzumab for follicular lymphoma in leukemic phase

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2023

Establishment and Characterization of an Acute Lymphocytic Leukemia Cell Line Expressing CD13 and CD33 with a Complex Philadelphia Translocation.

Establishment and Characterization of an Acute Lymphocytic Leukemia Cell Line Expressing CD13 and CD33 with a Complex Philadelphia Translocation.

Journal: Internal medicine (Tokyo, Japan)

Published: March 01, 2023

Genetic alterations in patients with chronic leucocytosis and persistent thrombocytosis.

Genetic alterations in patients with chronic leucocytosis and persistent thrombocytosis.

Journal: Journal of genetics

Published: February 07, 2022

High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.

High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.

Journal: Leukemia & lymphoma

Published: May 20, 2021

Successful Rituximab Treatment in Thrombotic Thrombocytopenic Purpura Patients Complicated by Other Autoimmune Disorders: Two Case Reports.

Successful Rituximab Treatment in Thrombotic Thrombocytopenic Purpura Patients Complicated by Other Autoimmune Disorders: Two Case Reports.

Journal: Internal medicine (Tokyo, Japan)

Published: March 29, 2021

Very Early Increased Platelet Count within a Week after Initiation of High-Dose Dexamethasone Treatment Is Associated with Long-Term Response in Newly Diagnosed Immune Thrombocytopenia Patients.

Very Early Increased Platelet Count within a Week after Initiation of High-Dose Dexamethasone Treatment Is Associated with Long-Term Response in Newly Diagnosed Immune Thrombocytopenia Patients.

Journal: Acta haematologica

Published: December 23, 2020

Correction to: Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.

Correction to: Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.

Journal: Annals of hematology

Published: September 27, 2020

Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.

Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.

Journal: Annals of hematology

Published: May 01, 2020

Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.

Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.

Journal: Haematologica

Published: August 11, 2019

Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes.

Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes.

Journal: Cancer medicine

Published: April 11, 2019

Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.

Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.

Journal: Leukemia research

Published: March 15, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026